Advertisement
Singapore markets open in 3 hours 31 minutes

  • Straits Times Index

    3,292.69
    +10.64 (+0.32%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • Dow

    37,903.29
    +87.37 (+0.23%)
     

  • Nasdaq

    15,605.48
    -52.34 (-0.33%)
     

  • Bitcoin USD

    57,859.06
    -2,290.12 (-3.81%)
     

  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     

  • FTSE 100

    8,121.24
    -22.89 (-0.28%)
     

  • Gold

    2,330.20
    +27.30 (+1.19%)
     

  • Crude Oil

    79.13
    -2.80 (-3.42%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • Nikkei

    38,274.05
    -131.61 (-0.34%)
     

  • Hang Seng

    17,763.03
    +16.12 (+0.09%)
     

  • FTSE Bursa Malaysia

    1,575.97
    -6.69 (-0.42%)
     

  • Jakarta Composite Index

    7,234.20
    -7,155.78 (-49.73%)
     

  • PSE Index

    6,700.49
    -69.15 (-1.02%)
     

Endo starts manufacturing Novavax's potential COVID-19 vaccine

Reuters
Updated ·1-min read
FILE PHOTO: A small bottle labeled with a "Vaccine" sticker is held near a medical syringe in front of displayed "Coronavirus COVID-19" words in this illustration

(Reuters) - Generic drugmaker Endo said on Friday it was manufacturing Novavax Inc's <NVAX.O> experimental COVID-19 vaccine, sending its shares up 10% before the trading bell.

The news comes a day after Novavax launched a late-stage trial of the vaccine candidate, NVX‑CoV2373, in the United Kingdom.

Endo said it has signed a deal with Novavax and its unit Par Sterile has begun production of the final drug product, with initial batches to be used in Novavax's phase-3 clinical trial in the United States.

Financials and other terms of the non-exclusive agreement were not disclosed.

NVX‑CoV2373 is currently also being tested in two ongoing mid-stage trials that began in August.

(Reporting by Manas Mishra and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)